Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Julia Yemelyanenko"'
Autor:
Sjoerd Klarenbeek, Chris W. Doornebal, Sjors M. Kas, Nicola Bonzanni, Jinhyuk Bhin, Tanya M. Braumuller, Ingrid van der Heijden, Mark Opdam, Philip C. Schouten, Kelly Kersten, Roebi de Bruijn, Daniel Zingg, Julia Yemelyanenko, Lodewyk F.A. Wessels, Karin E. de Visser, Jos Jonkers
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy. Phosphoinositide 3-kinase (PI3K) signaling, one of the major druggable oncoge
Externí odkaz:
https://doaj.org/article/54b9a172c50d4990871cfc2608c09c9c
Autor:
Daniel Kaspar Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Catrin Lutz, Chi-Chuan Lin, Sjoerd Klarenbeek, Jessica K. Lee, Ian M. Silverman, Stefano Annunziato, Marieke van de Ven, Siraj M. Ali, Timothy C. Burn, Shridar Ganesan, Lodewyk F. Wessels, Jos Jonkers
Publikováno v:
Cancer Research. 83:3488-3488
Human cancers frequently bear driver alterations in genes encoding receptor tyrosine kinases (RTKs), which has led to effective therapeutics targeting oncogenic signaling of RTK variants. Somatic hotspot mutations and structural amplifications and fu
Autor:
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers
Publikováno v:
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 609(7929), E13. Springer Nature 10.1038/s41586-022-05287-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42007ac1db1800b2f49158a1d120fdb2
Autor:
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers
Publikováno v:
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), pp. 609-617. Springer Nature 10.1038/s41586-022-05066-5
Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5
Nature, 608(7923), 609-617. Nature Publishing Group
Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5
Nature, 608(7923), 609-617. Nature Publishing Group
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1. However, clinical responses to FGFR inhibitors have remained variable1–9, emp
Autor:
Arjan W. Griffioen, Elisabeth J. M. Huijbers, Karlijn van Loon, Julia Yemelyanenko-Lyalenko, Coert Margadant
Publikováno v:
van Loon, K, Yemelyanenko-Lyalenko, J, Margadant, C, Griffioen, A W & Huijbers, E J M 2020, ' Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disorders ', Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1873, no. 2, 188354 . https://doi.org/10.1016/j.bbcan.2020.188354
Fibrillins constitute a family of large extracellular glycoproteins which multimerize to form microfibrils, an important structure in the extracellular matrix. It has long been assumed that fibrillin-2 was barely present during postnatal life, but it
Autor:
Sjors M. Kas, Mark Opdam, Lodewyk F. A. Wessels, Julia Yemelyanenko, Kelly Kersten, Nicola Bonzanni, Philip C. Schouten, Karin E. de Visser, Jos Jonkers, Chris W. Doornebal, Sjoerd Klarenbeek, Jinhyuk Bhin, Roebi de Bruijn, Ingrid van der Heijden, Tanya M. Braumuller, Daniel Zingg
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, 9(1)
Oncoimmunology
OncoImmunology, 9(1)
Oncoimmunology
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy. Phosphoinositide 3-kinase (PI3K) signaling, one of the major druggable oncoge